Conditions: Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 48
Healthy volunteers: no

Brief summary:
A study to evaluate the response of growth factor signatures (GFS) to a single dose of dalotuzumab in participants with triple negative (TN) or estrogen receptor (ER)-positive luminal B breast cancer. The primary hypothesis is that dalotuzumab will induce a decrease in the GFS in at least 40% of participants.

Detailed description:

Arms:
arm 1: Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes. arm 2: Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.

Interventions: intervention 1: dalotuzumab (MK0646)
Intervention descriptions: intervention 1: Single intravenous infusion

Protocol document: